Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine

AAPS PharmSciTech

Volumn 15, Issue 2, 2014, Pages 317-325

  Sawaengsak, Chompoonuch ^a,c   Mori, Yasuko ^b,c   Yamanishi, Koichi ^c   Mitrevej, Ampol ^a   Sinchaipanid, Nuttanan ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

chitosan nanoparticles; delivery systems; influenza virus; intranasal; split influenza vaccine

Indexed keywords

CHITOSAN; GAMMA INTERFERON; HEMAGGLUTININ; HEMAGGLUTININ SPLIT INFLUENZA VIRUS MUCOSAL VACCINE; INFLUENZA VACCINE; NANOPARTICLE; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS LINKING; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; MOUSE; MUCOSAL IMMUNITY; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; SECRETORY CELL; SPLEEN; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY;

ANIMALS; ANTIBODIES, VIRAL; CHITOSAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NANOPARTICLES; RESPIRATORY MUCOSA;

EID: 84898010025     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-0058-7     Document Type: Article

References (60)

1. Gasparini R, Amicizia D, Lai PL, Panatto D. Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly. Hum Vaccin Immunother. 2012;8:21-8.
2. Wong SS, Webby RJ. Traditional and new influenza vaccine. Clin Microbiol Rev. 2013;26:476-92.
3. Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis. 1977;136:623-32.
4. Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics. 1982;69:404-8.
5. Kim YK, Eun BW, Kim NH, Kang EK, Lee BS, Kim DH, et al. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months. Scand J Infect Dis. 2013;45:460-8.
6. Wright PF. The use of inactivated influenza vaccine in children. Semin Pediatr Infect Dis. 2006;17:200-5.
7. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012-13 influenza season. Morb Mortal Wkly Rep. 2012;61:613-8.
8. Neuzil KM, Jackson LA, Nelson J, Kilmov A, Cox N, Bridges CB, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006;194:1032-9.
9. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet. 2001;357:1937-43.
10. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A,Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28:563-71.
11. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M,Hagan DT, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 2011;29:1812-23.
12. Lippi G, Targher G, Franchinni M. Vaccination, squalene and anti-squalene antibodies: facts or fiction? Eur J Intern Med. 2010;21:70-3.
13. Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus. 2012;21:217-22.
14. Waschbisch A, Wintterle S, Lochmüller H, Walter MC, Wischhusen J, Kieseier BC. Human muscle cells express the costimulatory molecule B7-H3, which modulated muscle-immune interactions. Arthritis Rheum. 2008;58:3600-8.
15. Davis SS. Nasal vaccines. Adv Drug Deliv Rev. 2001;51:21-42.
16. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol. 2004;4:699-710.
17. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6:148-58.
18. Svindland SC, Jul-Larsen Å, Pathirana R, Anderson S, Madhun A, Montomoli E, et al. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses. 2011;6:90-100.
19. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, et al. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine. 2007;25:144-53.
20. Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC. Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. Mol Pharm. 2012;9:81-90.
21. Yang X, Yuan X, Cai D, Wang S, Zong L. Low molecular weight chitosan in DNA vaccine delivery via mucosa. Int J Pharm. 2009;375:123-32.
22. van der Lubber IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci. 2001;14:201-7.
23. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev. 2005;57:411-30.
24. Sui Z, Chen Q, Fang F, Zheng M, Chen Z. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine. 2010;28:7690-8.
25. Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen A, et al. A study of chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses. 2012. doi: 10.1111/irv.12056.
26. Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol. 2012;19:979-90.
27. Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63:125-32.
28. Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, et al. Poly(γ-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine. 2009;27:5896-905.
29. Okamoto S, Yoshii H, Akagi T, Akashi M, Ishikawa T, Okuno Y, et al. Influenza hemagglutinin vaccine with poly(γ-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine. 2007;25:8270-8.
30. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccine. Vaccine. 2003;21:1769-75.
31. Horton RE, Vidarsson G. Antibodies and their receptors: different potential roles in mucosal defense. Front Immunol. 2013;4:200.
32. Rodríquez A, Tjärnlund A, Ivanji J, Singh M, García I, Williams A, et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine. 2005;23:2565-72.
33. Hagenaars N, Mastrobattista E, Verheul RJ, Mooren I, Glansbeek HL, Heldens JG, et al. Physicochemical and immunological characterization of N, N, N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration. Pharm Res. 2009;26:1353-64.
34. Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A. Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100. PLoS One. 2012;7:e52135. doi: 10.1371/journal.pone.0052135.
35. Sharma S, Mukkur TK, Benson HA, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci. 2009;98:812-43.
36. Wang X, Zhang W, Liu F, Zheng M, Zheng D, Zhang T, et al. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge. Arch Virol. 2012;157:1451-61.
37. Raghuwanshi D, Mishra V, Das D, Kaur K, Suresh MR. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. Mol Pharm. 2012;9:946-56.
38. Figueiredo L, Cadete A, Gonçalves LM, Corvo ML, Almeida AJ. Intranasal immunization of mice against Streptococcus equi using positively charged nanoparticulate carrier systems. Vaccine. 2012;30:6551-8.
39. Amidi M, Mastrobattista E, Jiskoot W, Hennick WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 2010;62:59-82.
40. Csaba N, Köping-Höggård M, Alonso MJ. Ionically cross-linked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. Int J Pharm. 2009;382:205-14.
41. Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm. 2003;250:215-26.
42. Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 2005;44:65-73.
43. Akbuǧa J, Bergisadi N. Effect of formulation variables on cis-platin loaded chitosan microsphere properties. J Microencapsul. 1999;16:697-703.
44. Garcia-Fuentes M, Alonso MJ. Chitosan-based drug nanocarriers: where do we stand? J Control Release. 2012;161:496-504.
45. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62:12-27.
46. Prego C, García M, Torres D, Alonso MJ. Transmucosal macromolecule drug delivery. J Control Release. 2005;101:151-62.
47. Vila A, Sánchez A, Janes K, Behrens I, Kissel T, Vila Jato JL, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm. 2004;57:123-31.
48. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release. 2003;87:187-98.
49. Forged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298:315-22.
50. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57:1556-68.
51. Davis SS. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine. 2006;24(2):S2-7-10.
52. De Temmerman ML, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today. 2011;16:569-82.
53. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976;143:1283-8.
54. Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine delivery carriers: insights and future perspectives. Int J Pharm. 2013;440:27-38.
55. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31:3657-66.
56. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res. 2004;21:671-4.
57. Durrey C, Irache JM, Puisieux F, Duchêne D, Ponchel G. Mucoadhesion of latexes. II. Adsorption isotherms and desorption studies. Pharm Res. 1994;11:680-3.
58. Sailaja AK, Amareshwar P, Chakravarty P. Chitosan nanoparticles as a drug delivery system. Res J Pharm Biol Chem Sci. 2010;1:474-84.
59. Källenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis. 2007;87:257-66.
60. Köping-Höggård M, Sánchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines. 2005;4:185-96.